Regulation of innate lymphoid cells in inflammation

Information

  • Research Project
  • 9858222
  • ApplicationId
    9858222
  • Core Project Number
    R01AI123398
  • Full Project Number
    5R01AI123398-05
  • Serial Number
    123398
  • FOA Number
    PAS-15-055
  • Sub Project Id
  • Project Start Date
    2/15/2016 - 9 years ago
  • Project End Date
    1/31/2021 - 4 years ago
  • Program Officer Name
    DAVIDSON, WENDY F
  • Budget Start Date
    2/1/2020 - 5 years ago
  • Budget End Date
    1/31/2021 - 4 years ago
  • Fiscal Year
    2020
  • Support Year
    05
  • Suffix
  • Award Notice Date
    1/16/2020 - 5 years ago

Regulation of innate lymphoid cells in inflammation

? DESCRIPTION (provided by applicant): Group 2 innate lymphoid cells (ILC2s) are recently characterized as a new subset of lymphoid cell populations, which play pivotal roles in inducing allergic inflammation, clearing infections, and repairing damaged tissues. They secrete type 2 cytokines including interleukins 5 and 13 and are controlled by transcription factors Gata3 and Ror?. These cells are present in both mouse and humans and are involved in various disease developments. However, the underlying cellular and molecular mechanisms of regulation remain largely unknown. Our long-term goal is to study the process of protein modification by the ubiquitin tagging in immune responses. We thus performed preliminary studies to explore the roles of E3 ubiquitin ligases in ILC2s by using conditional deletions of genes in mouse models, and found that the deficiency of VHL E3 ligase component results in defective development of ILC2s in the lungs, whereas loss of Fbw7, another E3 ligase component, caused defective differentiation in the bone marrow under steady state, and reduced lung ILC2 numbers upon allergen exposure. These preliminary studies indicate that the ubiquitin system is important for ILC2s, and allow us to hypothesize that they function at different stages of ILC2 differentiation via targeting the ubiquitination of their targets. To test this central hypothesis,we propose the following two major aims: Specific Aim 1: To study VHL in ILC2 maturation and function in the lungs. Specific Aim 2: To study Fbw7 in ILC2 development in the bone marrow and function in the lungs. We will use a combination of in vitro and in vivo feasible approaches, with complementary alternatives. The expected results will significantly move this field forward, and will have impact on the development of therapeutic methods and/or targets for inflammatory diseases and infection.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    250000
  • Indirect Cost Amount
    192500
  • Total Cost
    442500
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:442500\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    CMIB
  • Study Section Name
    Cellular and Molecular Immunology - B Study Section
  • Organization Name
    LA JOLLA INST FOR ALLERGY & IMMUNOLGY
  • Organization Department
  • Organization DUNS
    603880287
  • Organization City
    LA JOLLA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    920371387
  • Organization District
    UNITED STATES